C
Hold
4/11/2024Upgraded
Big Pharma Split Corp. (PRM.TO) was upgraded to C from C- on 4/11/2024 due to an increase in the volatility index, solvency index and valuation index. Debt to equity declined from 0.66 to 0.63.
C
Hold
10/23/2023Downgrade
Big Pharma Split Corp. (PRM.TO) was downgraded to C- from C on 10/23/2023 due to a significant decline in the valuation index, growth index and volatility index. EBIT declined 0.7% from -$270.9 to -$272.8, total revenue declined 0.68% from -$147.3 to -$148.3, and earnings per share declined from -$0.1681 to -$0.1692.
C
Hold
8/31/2021Upgraded
Big Pharma Split Corp. (PRM.TO) was upgraded to C from C- on 8/31/2021 due to a significant increase in the valuation index, growth index and efficiency index. Total revenue increased 3.09% from $983.9 to $1.01M, EBIT increased 3.09% from $796.6 to $821.2, and earnings per share increased from $0.8713 to $0.8982.
C
Hold
7/16/2021Downgrade
Big Pharma Split Corp. (PRM.TO) was downgraded to C- from C on 7/16/2021 due to a decline in the volatility index.
C
Hold
6/21/2021Upgraded
Big Pharma Split Corp. (PRM.TO) was upgraded to C from C- on 6/21/2021 due to an increase in the volatility index and total return index.
C
Hold
6/2/2021Downgrade
Big Pharma Split Corp. (PRM.TO) was downgraded to C- from C on 6/2/2021 due to a decline in the volatility index.
C
Hold
5/18/2021Upgraded
Big Pharma Split Corp. (PRM.TO) was upgraded to C from C- on 5/18/2021 due to an increase in the volatility index and total return index.
C
Hold
5/3/2021Downgrade
Big Pharma Split Corp. (PRM.TO) was downgraded to C- from C on 5/3/2021 due to a significant decline in the valuation index and growth index. EBIT declined 2.2% from -$118.4 to -$121, and total revenue declined 2.02% from -$34.7 to -$35.4.
C
Hold
11/9/2020None
Big Pharma Split Corp. (PRM.TO) was downgraded to C from U on 11/09/2020.
